iBio (IBIO) Stock Heads Up On COVID-19 Vaccine Update

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is screaming for the top in the market this morning, and for good reason. The company provided an update with regard to their work to develop a vaccine for COVID-19. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Pops On COVID-19 Vaccine Development Update

In the press release, iBio provided an update surrounding one of its proprietary vaccine candidates for the protection of infection from the SARS-CoV-2 virus, the virus that causes COVID-19.

In the release, the company reminded investors that it is investigating an array of adjuvants in combination with its proprietary lichenase carrier molecule. This molecule is fused to a coronavirus sbunit protein. Of course, the goal here is to prove that this technology is safe and effective in preventing viral infection and the development of COVID-19.

In particular, IBIO is developing the vaccine as a potential option for the most vulnerable populations, including the elderly.

Importantly, the company said that it has completed ten distinct preclinical study arms for the IBIO-21 antigen-adjuvant combinations. The preclinical results show that the combinations included were delivered via intramuscular and intranasal routes, with datasets now under evaluation.

So far, the company knows that anti-SARS-CoV-2 spike titers to IBIO-201 were observed 21 days after immunization. Moreover, titers continued to increase over the course of the 42-day study. Also, IBIO said that favorable Th1 and Th2 immune profiles were observed in these preclinical studies.

The company also went on to explain that early functional testing of mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays.

As a result of the positive data thus far, the company is planning to conduct additional testing of IBIO-201 antisera, including further evaluations of neutralizing titers in multiple formats. The company also said that significant immune profiling studies are ongoing to evaluate the safety and immune protection correlates, including anti-specific T cell responses and memory B cell testing.

This additional testing is taking place surrounding both candidates, IBIO-201 and IBIO 200, under a collaboration with the Texas A&M University System of laboratories. In a statement, Tom Isett, Chairman and CEO at iBio, had the following to offer:

We are encouraged by these pre-clinical data, which demonstrate IBIO-201’s ability to generate an immune response to SARS-CoV-2 sequences and neutralize protein interaction. We expect to gain more insight as we complete data analysis of both of our COVID-19 vaccine candidates.

This Is Huge News

iBio was one of the earlier companies to announce that it was developing a COVID-19 vaccine. Given the company’s partnerships and ownership of the FastPharming Facility, I’ve been excited about the company’s work in the space since it was announced.

Today’s update was very important. The company has been pretty silent for some time, leading many to lose faith in what they’re doing. However, the update this morning told us that the company is still aggressively working to bring one or both of its vaccines to market, and that this work is proving to be fruitful.

As a result of the company’s continued work and many competitive advnatages in the vaccine space, IBIO stock is one to keep your eye on.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.